BGB-A445

Phase 3Small molecule

BeiGene

BGB-A445 is one of 73 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsActive, not recruiting

Advanced MalignanciesEnrolling by invitation

Advanced Solid TumorsPhase 2

Active, not recruiting

Advanced MalignanciesPhase 3

Enrolling by invitation

Competition

Competitive Landscape

286 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

24 2

Tecentriq

Roche

Phase 2

11 3

Beyfortus

BeiGene

Phase 2

10 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

19 5

Erbitux

IImclone

Phase 2

14 6

Alimta

SShawn Eagle

Phase 2

12 7

Myrbetriq

Astellas

Phase 2

1 8

Tarceva

OOSI Pharmaceuticals

Phase 2

6 9

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

3 10

Inlyta

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT04215978·204 enrolled

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Active, not recruiting· BeiGene logo

BeiGene·Phase 1/2·NCT05661955·113 enrolled

Advanced Malignancies1 trial

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation·BBeOne Medicines·Phase 3·NCT04164199·430 enrolled

Non-Small Cell Lung Cancer1 trial

Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Completed· BeiGene logo

BeiGene·Phase 2·NCT05635708·418 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for BGB-A445. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGB-A445 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGB-A445. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeiGene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BeiGene

BGB-A445

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Solid Tumors2 trials

Advanced Malignancies1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News